60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent “The retrograde instillation of JELMYTO for the clinical management of low-grade upper tract urothelial ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...